The NKG2A-blocking antibody monalizumab, which targets this axis, has already shown promising results in clinical trials and (Borst et al., 2020) the HLA-E ligand has been recognized as a potential target for the treatment of multiple myeloma (Yang et al., 2021). This evidence concerns the gene KLRC1 and plasma cell myeloma.